Perception, Opportunity in Volatility - Research & Analysis on GNC Holdings Inc and CVS Caremark Corporation

HONG KONG-- - This morning, www.MarketFoundations.com announced new reports highlighting GNC Holdings Inc and CVS Caremark Corporation . Free research downloads are available at www.MarketFoundations.com/index.php?coa=GNC&cob=CVS ...

Beehive extract shows potential as prostate cancer treatment

( University of Chicago Medical Center ) An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine. Researchers combined traditional cancer research methods with cutting-edge proteomics to find that CAPE arrests early-stage prostate cancer by ...

Vermilionville Unveils Newest Living Exhibit

Bayou Vermilion District's Vermilionville, in collaboration with the Lafayette Parish Master Gardeners, invites the public to the grand opening of the historic village's newest living exhibit, the Healer's Garden. The grand opening will take place on Tuesday, May 8 at 5:30 p.m. at Vermilionville's Maison Acadienne with a ribbon cutting followed by refreshments and a guided tour of the garden ...

Insight: Cancer in Africa: Fighting a nameless enemy

ACCRA (Reuters) - In Emanuel Adu's language, Twi, people call the skin cancer that is invading his cheek and nose "sasabro". It means a disease that eats away at you. The 73-year-old former cocoa farmer has come to the Korle Bu Teaching Hospital in Accra, miles from his home, to be treated with one of the two radiotherapy machines in Ghana. "I had heavy bleeding and discharge from my nose. The ...

Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in ...

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO™ that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.